Login to Your Account

Amgen Chooses License Option In Nuvelo Deal For Alfimeprase

By Randall Osborne

Wednesday, November 3, 2004
Amgen Inc. opted for a license arrangement rather than an equal partnership with Nuvelo Inc. for the Phase III-ready clot-dissolver alfimeprase, the lead product candidate that is the subject of a deal started almost three years ago. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription